Vanda's strong financials and product lineup show promise, but management concerns and FDA disputes may hinder growth. Learn ...

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that a New Drug Application (NDA) was submitted to the U.S.

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at the American Academy of Neurology (AAN) ...

VNDA opened at $4.50 on Tuesday. Vanda Pharmaceuticals has a 12-month low of $3.87 and a 12-month high of $6.75. The firm has a market capitalization of $262.42 million, a P/E ratio of -14.06 and ...

Vanda Pharmaceuticals (VNDA) announced that a New Drug Application was submitted to the U.S. FDA requesting marketing approval of Bysanti for ...

Analysts' ratings for Vanda Pharmaceuticals VNDA over the last quarter vary from bullish to bearish, as provided by 5 analysts. Summarizing their recent assessments, the table below illustrates ...

WASHINGTON, March 31, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VNDA) today announced that a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA ...

Morningstar brands and products Company Portfolio ...